The South African pharmaceutical market is valued at about USD 2.5 billion and recorded a growth of 8% in FY 2011. Pharma Dynamics recorded revenues of ZAR 288 million (`1818 million) registering a growth of 32% over the previous year. This growth record has been significantly higher than the average pharma growth rate of 8% and higher than the average growth rate of 13% of the 10 largest generic companies. Pharma Dynamics consolidated business has grown by an outstanding 144% since acquisition.

Pharma Dynamics is ranked 19th in the South African Pharmaceutical market and 6th in the generic space with a clear focus in the Cardiovascular, Central Nervous System, Gastroenterology and the OTC segments.

Currently, Pharma Dynamics has 233 dossiers in registration process including many in multiple sub-Saharan African countries. Lupin’s planned move to backend production into our manufacturing facilities was successfully executed for two CVS products of Pharma Dynamics in the current year and 2 more products have been planned for the coming year. During FY 2011, Pharma Dynamics launched 6 new products. Pharma Dynamics will soon enter into new therapeutic areas of Female Healthcare, Injectables Antibiotics and Tuberculosis.

For more information log on to : www.pharmadynamics.co.za